IL17A and rheumatoid arthritis: The murine models of RA suggested that AHR activation with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) could contribute to RA disease severity, disease progression, osteoclasts differentiation, and increase the numbers of IL17-expressing cells in the inflamed joints (10).